This is the largest and most detailed study of 5-ASA-induced nephrotoxicity to date. It highlights the morbidity associated with this condition and identifies for the first time a significant genetic predisposition to drug-induced renal injury.
Background:Cases of de novo glomerular disease with various renal histologies have been reported after vaccination against SARS-CoV-2. Causality has not been established and the long-term outcomes are not known. To better characterize the glomerular diseases and clinical course/outcomes, we created the International Registry of COVID-19 vaccination and Glomerulonephritis (IRocGN2) to study in aggregate de novo glomerulonephritis cases suspected after COVID-19 vaccine exposure Methods:A RedCap survey was used for anonymized data collection. Detailed information on vaccination type and timing and glomerular disease histology were recorded in the registry. We collected serial information on laboratory values (before and after vaccination and during follow-up), treatments, and kidney-related outcomes. Results: Ninety-eight glomerular disease cases were entered into the registry over eleven months from 44 centers throughout the world. Median follow-up was 89 days after diagnosis. IgA nephropathy (IgAN) and minimal change disease (MCD) were the most the common kidney diseases reported. Recovery of kidney function and remission of proteinuria was more likely in IgAN and MCD at 4-6 months than with pauci immune glomerulonephritis /vasculitis and membranous nephropathy. Conclusions:Development of glomerular disease after vaccination against SARS-CoV-2 may be a very rare adverse event. Temporal association is present for IgAN and MCD, but causality is not firmly established. Kidney outcomes for IgAN and MCD are favorable. No changes in vaccination risk-benefit assessment is recommended based on these findings.
Background and Aims The incidence of acute kidney injury (AKI) is between 20-50% in a critically ill population. AKI is associated with increased risk of chronic kidney disease (CKD), end stage kidney disease (ESKD) and death. 30% of patients on ICU with AKI will have pre-existing CKD1. Arrangements for renal follow up of patients who develop AKI whilst on ICU vary between centres. We aimed to review the renal function pre admission and at one and two years after discharge for all patients who received renal replacement therapy (RRT) with haemofiltration or haemodialysis on ICU during 2016. We reviewed how many were under renal follow up and aimed to identify techniques to improve follow up if required. Method We reviewed electronic records of all patients who received RRT on the ICU during 2016. We assessed demographic details, renal function, details of ICU stay and co morbidities. We excluded patients who died on ICU or received RRT for non-renal indications. Patients who were not under renal follow up were offered a single renal clinic at 2 years (2018) after their ICU discharge. In 2019 we set up a monthly electronic alert to the renal team for all patients who have received haemofiltration on ICU. Each patient’s case was reviewed and either renal follow up arranged or letter sent to primary care and the patient to ensure a 1 year post discharge renal function check to risk stratify them. Results 64 patients received RRT therapy in ICU in 2016 of whom 20 died during their ICU stay and 4 received RRT for non-renal indications. 40 patients were included in further analysis. The median (IQR, range) age was 60(49.5-69.5, 20-87) years. 21/40(53%) were admitted to ICU for sepsis and 8/40(20%) had CKD (defined by eGFR<60), and 6/40(15%) had ESKD, (5 on haemodialysis, 1 transplanted) prior to admission. 33% had diabetes and 64% had vascular disease. 7 were known to the renal team prior to admission and 14/40 (35%) underwent renal follow up post discharge. Excluding those on RRT prior to admission, median (IQR, range) pre-admission eGFR was 82 (55->90, 30->90). 3 patients were discharged on RRT. The majority of patients who were discharged from hospital off RRT met eGFR criteria for CKD stage 3, data available for 30, median eGFR 56 (range: 10->90, IQR: 26-83), N=16/30(54%), p=0.01 compared to pre ICU stay had CKD stage 3 by eGFR criteria. By one year 2 of 3 patients were still on RRT. The majority of patients from hospital off RRT still met eGFR criteria for CKD stage 3, data available for 29, median eGFR 57 (range: 14->90, IQR: 39-77), N=15/29(52%) had CKD stage 3 by eGFR criteria. By 2 years, data available for 19, median GFR was 51 (range: 12->90, IQR: 32-86) with 11/19 (57%) meeting CKD stage 3 eGFR. Discharge eGFR was moderately correlated with 2 year follow up eGFR (r=0.49, p=0.03) and post discharge CKD stage 3 did not predict future CKD stage 3 (p=0.35) whereas eGFR at 1 year post discharge was much more strongly correlated with final follow up eGFR (spearman’s r=0.95, p<0.0001) and CKD stage 3 at 1 year predicted CKD at 2 years (p=0.003). Of those with CKD stage 3 at 2 years 5/11 (45%) were followed up in a renal clinic. In 2019, 34 electronic notifications were received. Primary care notified of 11 patients to ensure renal function measured at 1 year. 7 patients died, 8 patients already know to the renal team, 6 patients had new renal follow made at discharge and 2 patients had follow up under other medical specialities. Conclusion eGFR at 1 year post discharge from ICU is the best predictor of long term CKD and this could be used to target patients who need continued renal follow up. Electronic notifications from ICU can help accomplish this.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.